Background: A prime-boost regimen of recombinant canarypox priming (ALVAC-HIV) with HIV (Clade B and E) -gp120 protein boosting formulated in Alum resulted in significant but limited protection from HIV acquisition in the Thai Trial (RV144). We hypothesized that the use of the Th1/Th2- adjuvant MF59 as an alternative to the Th2- Alum, could improve the protection elicited by the ALVAC-SIV/ gp120 vaccine platform, by increasing envelope specific antibody and T cell responses. Methodology: We vaccinated 54 macaques four times (0,4, 12 and 24 weeks) with the identical ALVAC backbone used in RV144, expressing SIV mac251 Gag-pro and gp120TM (instead of the HIV-1 Envs used in RV144), and then boosted 27 macaques twice (12 and 24 weeks) with both SIVmac251- and SIVsmE660- gp120 proteins formulated either with Alum or with MF59. A total of 24 adjuvanted or naive animals were included as concurrent controls and additional 23 as historical controls. All the animals were exposed to 120 TCID50 of SIVmac251, by the intra-rectal route, once a week, at 4 weeks after the last immunization. Results: ALVAC-SIV/gp120 adjuvanted in MF59 significantly increased env-specific binding antibodies, ADCC, neutralizing antibodies, and CD4+ T-cell responses compared to the identical regimen adjuvanted in Alum. However the Alum-group induced significantly higher titers of envelope specific IgG3 antibodies in the plasma and cyclic V2 responses in mucosal compartments compared to the MF59-group. In addition, the Alum-group (RV144-like) resulted in significant protection from SIVmac251 acquisition (log rank p=0.021) while the MF59-group did not improve the efficacy of the ALVAC/gp120 regimen (log rank p=0.56) Conclusions: The combination of ALVAC-SIV-gp120/MF59 was overall more immunogenic than that of ALVAC-SIV-gp120/Alum; however it did not increase protection against SIVmac251 acquisition and altered both the IgG subclass and mucosal V2 responses.